These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 36100891)

  • 1. Immune checkpoint inhibitor (ICI) genes and aging in malignant melanoma patients: a clinicogenomic TCGA study.
    Safi M; Jin C; Aldanakh A; Feng P; Qin H; Alradhi M; Zhang L; Zhang J; Adlat S; Zhao Y; Liu J
    BMC Cancer; 2022 Sep; 22(1):978. PubMed ID: 36100891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Checkpoint Inhibitor (ICI) Genes and Aging in Clear Cell Renal Cell Carcinoma (ccRCC): Clinical and Genomic Study.
    Al-Danakh A; Safi M; Alradhi M; Chen Q; Baldi S; Zhu X; Yang D
    Cells; 2022 Nov; 11(22):. PubMed ID: 36429070
    [No Abstract]   [Full Text] [Related]  

  • 3. Age-Based Disparities in Metastatic Melanoma Patients Treated in the Immune Checkpoint Inhibitors (ICI)
    Safi M; Al-Azab M; Jin C; Trapani D; Baldi S; Adlat S; Wang A; Ahmad B; Al-Madani H; Shan X; Liu J
    Front Immunol; 2021; 12():609728. PubMed ID: 34887846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.
    Zhang L; Han X; Shi Y
    JAMA Netw Open; 2020 Aug; 3(8):e2013201. PubMed ID: 32845327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Innate immune checkpoint inhibitor resistance is associated with melanoma sub-types exhibiting invasive and de-differentiated gene expression signatures.
    Hossain SM; Gimenez G; Stockwell PA; Tsai P; Print CG; Rys J; Cybulska-Stopa B; Ratajska M; Harazin-Lechowska A; Almomani S; Jackson C; Chatterjee A; Eccles MR
    Front Immunol; 2022; 13():955063. PubMed ID: 36248850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
    Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
    JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma.
    Zhang W; Kong Y; Li Y; Shi F; Lyu J; Sheng C; Wang S; Wang Q
    Front Immunol; 2021; 12():798474. PubMed ID: 35087523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of age with survival in older patients with cutaneous melanoma treated with immune checkpoint inhibitors.
    Howell AV; Gebregziabher M; Thiers BH; Graboyes EM; Paulos CM; Wrangle JM; Hunt KJ; Wallace K
    J Geriatr Oncol; 2022 Sep; 13(7):1003-1010. PubMed ID: 35660090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Immune-Related Gene Pair Index Predicts Clinical Response and Survival Outcome of Immune Checkpoint Inhibitors in Melanoma.
    Yan J; Wu X; Yu J; Kong Y; Cang S
    Front Immunol; 2022; 13():839901. PubMed ID: 35280982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sex Disparities of Genomic Determinants in Response to Immune Checkpoint Inhibitors in Melanoma.
    Shi F; Zhang W; Yang Y; Yang Y; Zhao J; Xie M; Sheng C; Wang S; Wang Q
    Front Immunol; 2021; 12():721409. PubMed ID: 34795662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune-Related Adverse Events After Immune Checkpoint Inhibitors for Melanoma Among Older Adults.
    Schonfeld SJ; Tucker MA; Engels EA; Dores GM; Sampson JN; Shiels MS; Chanock SJ; Morton LM
    JAMA Netw Open; 2022 Mar; 5(3):e223461. PubMed ID: 35315916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting the clinical outcome of melanoma using an immune-related gene pairs signature.
    Meng L; He X; Zhang X; Zhang X; Wei Y; Wu B; Li W; Li J; Xiao Y
    PLoS One; 2020; 15(10):e0240331. PubMed ID: 33031392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.
    Wang SJ; Khullar K; Kim S; Yegya-Raman N; Malhotra J; Groisberg R; Crayton SH; Silk AW; Nosher JL; Gentile MA; Mehnert JM; Jabbour SK
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of an immunosuppressive therapy on the efficacy of immune checkpoint inhibition in metastatic melanoma - An analysis of the prospective skin cancer registry ADOREG.
    Kochanek C; Gilde C; Zimmer L; Ugurel S; Meier F; Utikal J; Pföhler C; Herbst R; Haferkamp S; Welzel J; Dücker P; Leiter U; Weichenthal M; von Wasielewski I; Angela Y; Gutzmer R
    Eur J Cancer; 2024 Feb; 198():113508. PubMed ID: 38183763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Impact of Immune Checkpoint Inhibitor (ICI) Response, DNA Damage Repair (DDR) Gene Mutations and Immune-Cell Infiltration in Metastatic Melanoma Subtypes.
    Andrieu C; McNamee N; Larkin AM; Maguire A; Menon R; Mueller-Eisert J; Horgan N; Kennedy S; Gullo G; Crown J; Walsh N
    Med Sci (Basel); 2022 May; 10(2):. PubMed ID: 35736346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
    Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA damage response-related immune activation signature predicts the response to immune checkpoint inhibitors: from gastrointestinal cancer analysis to pan-cancer validation.
    Yan J; Wang S; Zhang J; Yuan Q; Gao X; Zhang N; Pan Y; Zhang H; Liu K; Yu J; Lu L; Liu H; Gao X; Zhao S; Zhang W; Reyila A; Qi Y; Zhang Q; Cang S; Lu Y; Pan Y; Kong Y; Nie Y
    Cancer Biol Med; 2023 Dec; 21(3):252-66. PubMed ID: 38164720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eight gene mutation-based polygenic hazard score as a potential predictor for immune checkpoint inhibitor therapy outcome in metastatic melanoma.
    Zhao L; Luo T; Jiang J; Wu J; Zhang X
    Front Mol Biosci; 2022; 9():1001792. PubMed ID: 36120536
    [No Abstract]   [Full Text] [Related]  

  • 19. Synthetic viability induces resistance to immune checkpoint inhibitors in cancer cells.
    Liu M; Dong Q; Chen B; Liu K; Zhao Z; Wang Y; Zhuang S; Han H; Shi X; Jin Z; Hui Y; Gu Y
    Br J Cancer; 2023 Oct; 129(8):1339-1349. PubMed ID: 37620409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival.
    Sussman TA; Li H; Hobbs B; Funchain P; McCrae KR; Khorana AA
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33436486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.